Tesla reported mixed earnings, with the automotive company posting $.80 EPS and $10.74B in revenue, compared to consensus estimates of $1.03 EPS and $10.38B in revenue.
As we celebrate International Women's Day and this year's theme #ChooseToChallenge, Frost & Sullivan acknowledges the critical role of technology, such as artificial intelligence and big data analytics, in improving women's lives and empowering them.
(Bloomberg) -- A sophisticated attack on Microsoft Corp.’s widely used business email software is morphing into a global cybersecurity crisis, as hackers race to infect as many victims as possible before companies can secure their computer systems.The attack, which Microsoft has said started with a Chinese government-backed hacking group, has so far claimed at least 60,000 known victims globally, according to a former senior U.S. official with knowledge of the investigation. Many of them appear to be small or medium-sized businesses caught in a wide net the attackers cast as Microsoft worked to shut down the hack.The European Banking Authority became one of the latest victims as it said Sunday that access to personal data through emails held on the Microsoft server may have been compromised. Others identified so far include banks and electricity providers, as well as senior citizen homes and an ice cream company, according to Huntress, a Ellicott City, Maryland-based firm that monitors the security of customers, in a blog post Friday.One U.S. cybersecurity company which asked not to be named said its experts alone were working with at least 50 victims, trying to quickly determine what data the hackers may have taken while also trying to eject them.The rapidly escalating attack came months after the SolarWinds Corp. breaches by suspected Russian cyberattackers, and drew the concern of U.S. national security officials in part because the latest hackers were able to hit so many victims so quickly. Researchers say in the final phases of the attack, the perpetrators appeared to have automated the process, scooping up tens of thousands of new victims around the world in a matter of days.Washington is preparing its first major moves in retaliation against foreign intrusions over the next three weeks, the New York Times reported, citing unidentified officials. It plans a series of clandestine actions across Russian networks -- intended to send a message to Vladimir Putin and his intelligence services -- combined with economic sanctions. President Joe Biden could issue an executive order to shore up federal agencies against Russian hacking, the newspaper reported.“We are undertaking a whole of government response to assess and address the impact,” a White House official wrote in an email on Saturday. “This is an active threat still developing and we urge network operators to take it very seriously.”Read more: Preparing for Retaliation Against Russia, U.S. Confronts Hacking by ChinaThe Chinese hacking group, which Microsoft calls Hafnium, appears to have been breaking into private and government computer networks through the company’s popular Exchange email software for a number of months, initially targeting only a small number of victims, according to Steven Adair, head of the northern Virginia-based Volexity. The cybersecurity company helped Microsoft identify the flaws being used by the hackers for which the software giant issued a fix on Tuesday.The result is a second cybersecurity crisis coming just months after suspected Russian hackers breached nine federal agencies and at least 100 companies through tampered updates from IT management software maker SolarWinds LLC. Cybersecurity experts that defend the world’s computer systems expressed a growing sense of frustration and exhaustion.‘Getting Tired’“The good guys are getting tired,” said Charles Carmakal, a senior vice president at FireEye Inc., the Milpitas, California-based cybersecurity company.Asked about Microsoft’s attribution of the attack to China, a Chinese foreign ministry spokesman said Wednesday that the country “firmly opposes and combats cyber attacks and cyber theft in all forms” and suggested that blaming a particular nation was a “highly sensitive political issue.”Read more: Microsoft Server Flaws Raise Alarms at White House, DHS Both the most recent incident and the SolarWinds attack show the fragility of modern networks and sophistication of state-sponsored hackers to identify hard-to-find vulnerabilities or even create them to conduct espionage. They also involve complex cyberattacks, with an initial blast radius of large numbers of computers which is then narrowed as the attackers focus their efforts, which can take affected organizations weeks or months to resolve.In the case of the Microsoft bugs, simply applying the company-provided updates won’t remove the attackers from a network. A review of affected systems is required, Carmakal said. And the White House emphasized the same thing, including tweets from the National Security Council urging the growing list of victims to carefully comb through their computers for signs of the attackers.Initially, the Chinese hackers appeared to be targeting high value intelligence targets in the U.S., Adair said. About a week ago, everything changed. Other unidentified hacking groups began hitting thousands of victims over a short period, inserting hidden software that could give them access later, he said.‘Mass Exploitation’“They went to town and started doing mass exploitation -- indiscriminate attacks compromising exchange servers, literally around the world, with no regard to purpose or size or industry,” Adair said. “They were hitting any and every server that they could.”Adair said that other hacking groups may have found the same flaws and began their own attacks -- or that China may have wanted to capture as many victims as possible, then sort out which had intelligence value.Either way, the attacks were so successful -- and so rapid -- that the hackers appear to have found a way to automate the process. “If you are running an Exchange server, you most likely are a victim,” he said.Data from other security companies suggest that the scope of the attacks may not end up being quite that bad. Researchers from Huntress examined about 3,000 vulnerable servers on its partners’ networks and found about 350 infections -- or just over 10%.While the SolarWinds hackers infected organizations of all sizes, many of the latest batch of victims are small-to medium-sized business and local government agencies. Organizations that could be most impacted are those that have an email server that’s running the vulnerable software and exposed directly to the internet, a risky setup that larger ones usually avoid.Smaller organizations are “struggling already due to Covid shutdowns -- this exacerbates an already bad situation,” said Jim McMurry, founder of Milton Security Group Inc., a cybersecurity monitoring service in Southern California. “I know from working with a few customers that this is consuming a great deal of time to track down, clean and ensure they were not affected outside of the initial attack vector.”McMurry said the issue is “very bad” but added that the damage should be mitigated somewhat by the fact that “this was patchable, it was fixable.”Microsoft said customers that use its cloud-based email system are not affected.The use of automation to launch very sophisticated attacks may mark a new, frightening era in cybersecurity, one that could overwhelm the limited resources of defenders, several experts said.Some of the initial infections appear to have been the result of automated scanning and installation of malware, said Alex Stamos, a cybersecurity consultant. Investigators will be looking for infections that led to hackers taking the next step and stealing data -- such as e-mail archives -– and searching them for any valuable information later, he said.“If I was running one of these teams, I would be pulling down email as quickly as possible indiscriminately and then mining them for gold,” Stamos said.(Updates with potential U.S. retaliation from the sixth paragraph)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
AMS (formerly Alexander Mann Solutions), a global provider of talent outsourcing and advisory services, announces a strategic partnership with Revature, a leading technology talent development company. The new alliance enables clients to address the technology skills shortage by expanding the skills of new and existing talent, enabling organisations to better compete in the future of work.
Clean Air Metals Inc. ("Clean Air Metals" or the "Company") (TSXV: AIR) (OTCQB: CLRMF) (FRA: CKU) is pleased to announce that, further to its news release dated January 20, 2021, the Company has filed a technical report detailing the Mineral Resource estimate for the Thunder Bay North Project near Thunder Bay, Ontario.
Emmy-nominated Collins has had success over the years with the BET Awards, the Grammy Awards and various TV specials, and now he’s bringing his magical touch to the 2021 Academy Awards, thanks to a co-sign from the queen of all media. “I got an email from Oprah saying, ‘What’s your cell?,’” Collins recalled to The Associated Press.
Before posting a selfie with her COVID-19 vaccination card on Twitter, Aditi Juneja debated whether to include an explanation for why she was eligible for a shot. “The first draft of the tweet had an explanation,” says Juneja, a 30-year-old lawyer in New York City. After some thought, she decided to leave out out that her body mass index is considered obese, putting her at higher risk of serious illness if infected.
Webselenese is pleased to announce it is joining the Kape Technologies family as part of a transaction worth a total consideration of $149.1 million.
Pneumagen Ltd, a biotech company developing a universal pan-viral intranasal drug for protection against respiratory tract infections (RTIs), today announced a further milestone in the development of Neumifil™ for the treatment of COVID-19. Utilizing a hamster model of COVID-19 infection, researchers showed Neumifil was efficacious, significantly reducing clinical signs and weight loss in animals infected with SARS-CoV-2.
Designation confers advantages including marketing exclusivity and tax credits Padeliporfin ImPACT pivotal Phase 3 trial in UTUC to start end Q1 2021 LUXEMBOURG, March 08, 2021 (GLOBE NEWSWIRE) -- Steba Biotech, the IMmune Photo Activate Cancer Treatment (IMPACT) specialist today announces the U.S. Food and Drug Administration granted Orphan Drug Designation (ODD) to Padeliporfin ImPACT for the treatment of adult patients with Upper Tract Urothelial Cancer (UTUC). The FDA has already given the green light to the Investigational New Drug (IND) application, allowing initiation of the pivotal Phase 3 clinical trial of Padeliporfin ImPACT in patients with low-grade UTUC, which is expected to begin enrollment later this month. Padeliporfin ImPACT has also received Fast Track designation from the FDA for the treatment of adult patients with low-grade and unifocal high-grade UTUC. Orphan drug status confers a number of advantages for product development, including a tax credit for the cost of clinical trials undertaken in the US, marketing exclusivity for seven years, written recommendations from the FDA on clinical and preclinical studies needed for approval and a fast-track procedure for regulatory review. Barak Palatchi, CEO of Steba Biotech, said, “We are delighted to receive Orphan Drug Designation for Padeliporfin ImPACT in UTUC, further validating Steba’s technology and the benefits our product could bring to people suffering from UTUC. It has been less than a year since we embarked on our new strategy, refocusing Padeliporfin ImPACT on diseases for patients with limited treatment options. In UTUC, the current standard of care is nephrectomy; our hope is that Padeliporfin ImPACT offers these patients an effective treatment option that preserves their kidney. UTUC is the first indication of our ambitious 3-year plan. We are looking forward to exploring the possibility of offering Padeliporfin ImPACT to more patients coping with life threatening cancers.” Steba is focusing on the development of Padeliporfin ImPACT as an innovative oncology platform with the potential to offer surgery-like efficacy, combined with organ preservation in UTUC and other solid tumors for high-risk surgical patients with unmet needs – either because surgery is not the preferred clinical option (e.g., to delay the loss of a kidney) or the risk of surgery is too high. About Padeliporfin ImPACT Padeliporfin ImPACT (Immune Photo Activated Cancer Therapy) offers surgery-like efficacy combined with organ preservation. ImPACT is Steba’s oncology platform comprising the intravenous delivery of an inactive drug, padeliporfin. Upon activation, the drug rapidly triggers the constriction of the blood supply in the illuminated area only, resulting in targeted tumor necrosis that activates anti-tumor immunity which enhances cancer cell eradication. About UTUC Upper tract urothelial carcinoma (UTUC) is a type of cancer that grows either from the urothelium, a thin, continuous, protective layer of cells which line the ureter from kidney to bladder or the kidney lining itself1. UTUC obstructs the flow of urine from the kidney causing severe flank pain and blood to appear in urine, which may not be visible with the naked eye and delays diagnosis2. It currently accounts for 5-10 percent of urinary tract cancers3, but prognosis, already worse than bladder cancer, has been worsening over time, increasing the strain on healthcare services4. About Steba biotech Steba biotech is a Luxembourg based biotech organization founded in 1996 with operations in the EU, Israel and the US. Steba biotech is focused on the development of a novel oncology platform to treat a range of solid tumors with padeliporfin ImPACT (Immune Photo Activated Cancer Therapy). Under the guidance of a new leadership team, Steba biotech is implementing a bold three-year strategy concentrating on a range of solid tumors with a high medical need such as UTUC, lung and esophagus. Steba biotech’s strong relationships with The Weizmann Institute in Israel and Memorial Sloan Kettering Cancer Center in the US have produced exciting early results in a range of solid tumor types, including UTUC, esophageal, and lung. These early programs are now being accelerated into the clinic, supported by the safety and efficacy profile already established during earlier research in low-risk prostate cancer. 1. Upper Tract Urothelial Carcinoma. (n.d.). Accessed January 8, 2021; https://www.urotoday.com/library-resources/upper-tract-urothelial-carcinoma/109835-upper-tract-urothelial-carcinoma.html.2. Taylor, W. S. (2019). Delays to Diagnosis and Management of Upper Tract Urothelial Carcinoma. Journal of Endoluminal Endourology, 2(3), e5–e11. https://doi.org/10.22374/jeleu.v2i3.45.3. Soria, F., Shariat, S. F., Lerner, S. P., Fritsche, H.-M., Rink, M., Kassouf, W., Thalmann, G. N. (2016). Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC). World Journal of Urology, 35(3), 379–387. doi: 10.1007/s00345-016-1928-x.4. Eylert, M., Hounsome, L., Verne, J., Bahl, A., Jefferies, E., & Persad, R. (2013). Prognosis is deteriorating for upper tract urothelial cancer: data for England 1985-2010. BJU International, 112(2), E107-E113. doi: 10.1111/bju.12025. Contacts Chief Commercial Officer (BD & IR)Chris Grimes-Cromptonc.grimes-crompton@stebabiotech.comInvestor RelationsLifeSci AdvisorsGuillaume van Renterghemgvanrenterghem@lifesciadvisors.com +41 76 735 01 31 DisclaimerThis press release contains certain forward-looking statements concerning Steba Biotech and its business. Such forward looking statements are based on assumptions that Steba considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks and to the development of economic conditions, financial markets and the markets in which Steba operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Steba or not currently considered material by Steba. The occurrence of all or part of such risks could cause actual results, financial conditions, performance, or achievements of Steba to be materially different from such forward-looking statements. This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Steba shares in any country. The communication of this press release in certain countries may constitute a violation of local laws and regulations. Any recipient of this press release must inform oneself of any such local restrictions and comply therewith.
Today, Excelya has announced that it has appointed Nathalie Doize as Director of Operations and Rudolph Rosenberg as Chief Financial Officer at Excelya. Following strong growth in 2020, Nathalie will aim to harmonize operations across Europe and oversee project delivery as Excelya aims to become the highest quality contract research organization across Europe. Rudolph Rosenberg will define group financial strategy and help Excelya scale up its business globally.
The latest mobile app for content sales, qrush.com, is paying 90% of sales to creators for all of 2021. "We are aware 2020 was a hard year for everyone and many people lost their jobs and are looking for ways to make ends meet. That's why we decided to give up on platform fees and cover all operating expenses for 2021, so we can pay all creators 90% of sales, while 10% covers the acquisition, refund and payment costs," is the first thing Jim Austin, CEO of qrush, mentioned.
Toronto, Ontario--(Newsfile Corp. - March 8, 2021) - Compel Capital who through its wholly-owned subsidiary, ScreenPro Security (CSE: SCRN) ("ScreenPro" or the "Company"), is pleased to inform shareholders of its current business in Canada. The Company processed approximately 12,000 tests per week with weekly revenue over $1.2 million between Toronto and Vancouver in February 2021. John McMullen, CEO, stated: "This has been a very busy time for ScreenPro and I am very pleased for ...
HomeServe Japan, a JV between HomeServe plc and Mitsubishi Corporation, has signed its second utility partnership with Tohoku Electric Power.
Leading patient outcomes journal Patient Preference and Adherence has published a study that demonstrates significant improvement in treatment behaviors among patients with neovascular age-related macular degeneration (nAMD) who received personalized support in managing the practical and emotional impact of nAMD compared with those receiving usual care. Atlantis Healthcare, a global company specializing in the design and delivery of personalized support solutions to patients and caregivers living with chronic illness, operates the SmartSight program, which is sponsored and funded by Bayer Australia Ltd.
Results reinforce the importance of continuing eye care routines to maintain good eye health
Biocomposites, an international medical device company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue, today announces the appointment of Davina Lawrence to the newly created role of National Sales Director, UK, to drive its UK expansion.
Sandbox, a digital learning products and services company, has announced the addition of the Code Kingdoms to their growing product offering. Code Kingdoms is the UK’s leading provider of online programming and computer science resources for young people, and will join market leaders Poptropica and CoolMathGames as part of Sandbox Gaming, one of the three key verticals within Sandbox alongside Kids and Learning.
OKLAHOMA CITY, March 08, 2021 (GLOBE NEWSWIRE) -- Cytovance® Biologics, a leading biopharmaceutical contract development and manufacturing organization (CDMO) of mammalian, microbial biologics and gene therapy plasmid DNA (pDNA), announces a licensing opportunity for pDNA manufacturing. The Keystone Expression System® pDNA platform is an end-to-end solution for manufacturing GMP pDNA at scale in a manufacturer’s own facility. “This is a great opportunity for biologics manufacturers to reduce the time and cost of getting their pDNA products to market through the use of our perfected manufacturing process,” stated Matt Delaney, Vice President of Business Development and Marketing for Cytovance. “Our platform is uniquely designed to process plasmids with low shear lysis and purification steps to produce high-quality, high-yield pDNA,” Mr. Delaney added. License opportunities are currently available for either a 30L or 300L manufacturing scale. Each license includes end-to-end documentation including process descriptions, analytical standard operating procedures, critical equipment lists, facility layout, and much more. To ensure that pDNA manufacturing can begin quickly, Cytovance also offers hands-on process training, with our experts, at the manufacturer’s facility. To learn more about Cytovance Biologics and the opportunity for pDNA Manufacturing Licensing, visit https://www.cytovance.com/about-us. About Cytovance® Biologics Cytovance® Biologics is a leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO) that excels in the rapid and cost-effective development and manufacture of large molecule active pharmaceutical ingredients (APIs) from both mammalian cell culture and microbial fermentation such as monoclonal antibodies, fragment antibodies, bispecifics, enzymes, fusion proteins, vaccines and other biological products including plasmid DNA and cell-based therapeutics. In addition to its clinical and commercial CGMP API manufacturing services, Cytovance offers well-integrated development services supporting the entire product lifecycle including cell line development, cell banking, microbial strain development, process and analytical development, and process characterization. A centralized, responsive program management team coordinates all critical chemistry manufacturing and controls (CMC) activities for each client program around raw materials management, QC testing, ICH stability studies, and regulatory support. Our 140,000 sq. ft. state-of-the-art facilities in Oklahoma City are designed to meet U.S., EU, and other global regulatory standards. Cytovance offers deep industry expertise and unique customized services for the scale-up and CGMP manufacture of protein-based therapeutics; from early-stage pre-clinical development to commercial production, for both mammalian and microbial. Further information can be found at www.cytovance.com. Media Contact: Jodie Gutkowski Tel: 405-319-8309 E-mail: jgutkowski@cytovance.com
Molekule, the leader in reinventing air purification, today announced a giveaway program to benefit small- and medium-sized businesses. Businesses urgently need clean air solutions to help protect the environment for their customers and staff. Beginning March 8, 2021, Molekule will donate up to 4,000 Air Mini air purification devices, worth over $1.5 million in total, to help businesses reopen with cleaner air as pandemic shutdowns begin to ease. During this nomination period, existing customers who have purchased a device prior to the giveaway start date, are eligible to nominate a small business to receive an Air Mini device for their storefront.
Maxion Wheels, the world’s largest wheel manufacturer, reported today it completed the construction and infrastructure of its new Maxion Jantaş 21,000 sq. meters commercial vehicle (CV) steel wheels plant in Manisa, Turkey. Maxion Wheels, together with its partner Inci Holding, previously announced the expansion during the groundbreaking of newly acquired land, and today reports, the expansion is scheduled for completion in the first quarter of 2022, increasing Maxion Jantaş’ total production capacity to up to three million CV steel wheels a year.
Yahoo Home